Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
600 participants
OBSERVATIONAL
2019-04-05
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy
NCT03337100
The Impact of a Web-Based Naloxone Intervention Under Standing Orders to Patients Prescribed Chronic Opioid Therapy
NCT03337009
Improving Availability of Intranasal Naloxone
NCT05877118
Piloting a Naloxone Intervention in Philadelphia
NCT03305497
Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital
NCT03518021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim A - Describe factors associated with: 1) lifetime history of access to and use of naloxone and 2) uptake of no-cost naloxone and OD response training. We will test the following hypotheses:
HypA1 - Naloxone knowledge and exposure history will vary at enrollment, potentially revealing disparities based on background factors (e.g., SES, ethnicity, age, neighborhood) and individual level factors (e.g., mental health diagnoses, opioid use disorder severity, duration of opioid use) HypA2 - Interest in OD response training and naloxone at baseline will vary by background and individual-level factors.
Aim B - Describe longitudinal relationships between naloxone exposure (access to and use of naloxone) and overdose risk behaviors. We will test the following hypothesis:
HypB1 - Naloxone access and use exposures will have measurable impacts on opioid OD-related risk behaviors over time, potentially varying in degree and direction across subgroups of PWUIO.
Aim C (Qualitative) - Explore barriers to naloxone uptake and any identified secondary impacts (e.g., compensatory risk taking, positive change after a naloxone exposure such as risk reduction or treatment-seeking) in terms of opioid users' own experiences and perceptions.
By employing a longitudinal and mixed-methods design capable of detecting naloxone exposure impacts and also illuminating the various mechanisms that may undergird them in participants' own terms, this project holds serious policy and direct service implications for the refinement of naloxone training programs and OD risk interventions that target PWUIO. This research also holds the potential to identify varying naloxone impacts among PWUIO of different social and behavioral groups-such as people who inject drugs (PWID) vs. prescription opioid misusers, older vs. younger (or shorter- vs. longer-term) PWUIO, and male vs. female users-and can inform future efforts to tailor prevention and education to these distinct subpopulations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People who use illicit opioids
The study will recruit an adult-age (18+) sample of 600 people who use illicit opioids (either heroin or prescription opioid analgesics without a doctor's prescription) in New York City using Respondent Driven Sampling.
Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.
At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.
At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current illicit opioid use (verified by rapid urine screen)
* Speak English
* Willing to participate
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brandeis University
OTHER
Drexel University
OTHER
New York University
OTHER
Rhode Island Hospital
OTHER
National Development and Research Institutes, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Bennett
Principal Investigator and Deputy Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Rosenblum
Role: STUDY_DIRECTOR
National Development & Research Institutes (NDRI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
270 West 25th Street
New York, New York, United States
National Development and Research Institutes, Inc.
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pouget ER, Bennett AS, Elliott L, Wolfson-Stofko B, Almenana R, Britton PC, Rosenblum A. Development of an opioid-related Overdose Risk Behavior Scale (ORBS). Subst Abus. 2017 Jul-Sep;38(3):239-244. doi: 10.1080/08897077.2017.1282914. Epub 2017 Jan 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
660
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.